louisiana semaglutide nausea class action Novo Nordisk is suing Eli Lilly over its GLP-1 ads, accusing the rival drugmaker of false advertising for claiming Lilly's Mounjaro and Zepbound outperform Novo's Ozempic and Wegovy. MORE BELOW ⬇️ Semaglutide New Orleans | Medical

Foundayo (orforglipron), another oral GLP-1 receptor agonist, provides maximum dosage flexibility without dietary restrictions

Early assessment is important as ED can indicate underlying cardiovascular disease, diabetes, or hormonal imbalances

The favorable effect on 3-point MACE was driven by a significant decrease in non-fatal stroke

When yeast overgrowth is present, any refined carbohydrates you eat help feed the hungry candida in the guts neighborhood

While a specific release date is unclear, experts estimate that Retatrutide could become available within the next few years, pending successful clinical trials and FDA approval